Circulating levels of PCSK9 are linked to dyslipidemia in T2DM, which we suggest is due to its unique physiological functions related to lipid metabolism, but its beneficial effects on metabolic organs cannot be ignored, and anti-PCSK9 treatments that focus on circulating PCSK9 have a minimal effect on the organs that are being targeted. Here, PCSK9 is linked to metabolic syndrome.